PEZZULLO DAVID 4

Accession 0001209191-21-009470

CIK 0001180262other

View on SEC.gov Company Profile

Filed

Feb 9, 7:00 PM ET

Accepted

Feb 10, 8:29 PM ET

Size

42.3 KB

Accession

0001209191-21-009470

Insider Transaction Report

Form 4

Period: 2021-02-08

HERBALIFE NUTRITION LTD.HLF

PEZZULLO DAVID

Chief Accounting Officer

Transactions

Exercise/Conversion
Common Stock
2021-02-08$26.64/sh+20,764$553,257→ 168,737 total
Tax Payment
Common Stock
2021-02-08$55.83/sh−13,743$767,272→ 154,994 total
Exercise/Conversion
Common Stock
2021-02-08$33.85/sh+6,816$230,722→ 161,810 total
Tax Payment
Common Stock
2021-02-08$55.83/sh−5,061$282,556→ 156,749 total
Exercise/Conversion
Common Stock
2021-02-08$39.79/sh+29,508$1,174,123→ 186,257 total
Tax Payment
Common Stock
2021-02-08$55.83/sh−24,579$1,372,246→ 161,678 total
Exercise/Conversion
Common Stock
2021-02-08$31.25/sh+43,668$1,364,843→ 205,346 total
Tax Payment
Common Stock
2021-02-08$55.83/sh−33,978$1,896,992→ 171,368 total
Exercise/Conversion
Common Stock
2021-02-08$28.59/sh+45,902$1,312,568→ 217,270 total
Tax Payment
Common Stock
2021-02-08$55.83/sh−34,614$1,932,500→ 182,656 total
Award
Common Stock
2021-02-08+35,642→ 218,298 total
Tax Payment
Common Stock
2021-02-08$55.83/sh−17,672$986,628→ 200,626 total
Sale
Common Stock
2021-02-10$56.73/sh−5,644$320,163→ 194,982 total
Sale
Common Stock
2021-02-10$57.61/sh−15,801$910,357→ 179,181 total
Sale
Common Stock
2021-02-10$58.35/sh−13,238$772,490→ 165,943 total
Exercise/Conversion
Stock Appreciation Rights
2021-02-08−20,764→ 0 total
Exercise: $26.64From: 2014-05-18Exp: 2021-05-18→ Common Stock (20,764 underlying)
Exercise/Conversion
Stock Appreciation Rights
2021-02-08−6,816→ 0 total
Exercise: $33.85From: 2015-03-01Exp: 2022-03-01→ Common Stock (6,816 underlying)
Exercise/Conversion
Stock Appreciation Rights
2021-02-08−29,508→ 0 total
Exercise: $39.79From: 2016-06-21Exp: 2023-12-19→ Common Stock (29,508 underlying)
Exercise/Conversion
Stock Appreciation Rights
2021-02-08−43,668→ 0 total
Exercise: $31.25From: 2019-05-09Exp: 2026-05-09→ Common Stock (43,668 underlying)
Exercise/Conversion
Stock Appreciation Rights
2021-02-08−45,902→ 0 total
Exercise: $28.59From: 2020-02-27Exp: 2027-02-27→ Common Stock (45,902 underlying)

Footnotes (16)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
[F10]The SARS were granted on March 1, 2012. 20% vested on March 1, 2013, 20% vested on March 1, 2014 and the remaining 60% vested on March 1, 2015.
[F11]Adjusted to reflect the Issuer's May 14, 2018 2-for-1 stock split. The SARs were previously reported as covering 14,754 shares at an exercise price of $79.58 per share.
[F12]The SARS were granted on December 19, 2013. 20% vested on June 21, 2014, 20% vested on June 21, 2015 and the remaining 60% vested on June 21, 2016.
[F13]Adjusted to reflect the Issuer's May 14, 2018 2-for-1 stock split. The SARs were previously reported as covering 21,834 shares at an exercise price of $62.51 per share.
[F14]The SARS were granted on May 9, 2016. 20% vested on May 9, 2017, 20% vested on May 9, 2018 and the remaining 60% vested on May 9, 2019.
[F15]Adjusted to reflect the Issuer's May 14, 2018 2-for-1 stock split. The SARs were previously reported as covering 22,951 shares at an exercise price of $57.19 per share.
[F16]The SARS were granted on February 27, 2017. 20% vested on February 27, 2018, 20% vested on February 27, 2019 and the remaining 60% vested on February 27, 2020.
[F2]Represents common shares earned by the Reporting Person in connection with the vesting of performance share units ("PSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan based on pre-established performance goals for a 2018-2020 performance period.
[F3]Units withheld to satisfy tax withholding obligations in connection with the vesting of PSUs.
[F4]This transaction was executed in multiple trades at prices ranging from $56.2100 to $56.9900. The price reported reflects the weighted average sale price of $56.7262. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F5]This transaction was executed in multiple trades at prices ranging from $57.0900 to $57.9900. The price reported reflects the weighted average sale price of $57.6139. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F6]This transaction was executed in multiple trades at prices ranging from $58.0000 to $58.6250. The price reported reflects the weighted average sale price of $58.3540. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F7]Adjusted to reflect the Issuer's May 14, 2018 2-for-1 stock split. The stock appreciation rights ("SARs") were previously reported as covering 10,382 shares at an exercise price of $53.29 per share.
[F8]The SARS were granted on May 18, 2011. 20% vested on May 18, 2012, 20% vested on May 18, 2013 and the remaining 60% vested on May 18, 2014.
[F9]Adjusted to reflect the Issuer's May 14, 2018 2-for-1 stock split. The SARs were previously reported as covering 3,408 shares at an exercise price of $67.70 per share.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

HERBALIFE NUTRITION LTD.

CIK 0001180262

→

Entity typeother

Related Parties

filerCIK 0001311282

Filing Metadata

Form type: 4
Filed: Feb 9, 7:00 PM ET
Accepted: Feb 10, 8:29 PM ET
Size: 42.3 KB

View on SEC.gov